Cyprus Mail
Health

Early cancer detection test could be a game-changer

writing hand liquid tube finger equipment 1358260 pxhere.com

The National Health Service will on Monday begin the world’s biggest trial of Grail Inc’s flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.

The Galleri test looks at the DNA in a patient’s blood to determine if any come from cancer cells. Earlier diagnosis of cancers leads to dramatically increased survival rates.

The NHS said it wanted to recruit 140,000 volunteers in England to see how well the test worked as part of a randomised control trial. Half of the participants will have their blood sample screened with the Galleri test right away.

“We need to study the Galleri test carefully to find out whether it can significantly reduce the number of cancers diagnosed at a late stage,” said Peter Sasieni, professor of cancer prevention at King’s College London.

“The test could be a game-changer for early cancer detection and we are excited to be leading this important research.”

Lung cancer is by far the most common cause of cancer death in the United Kingdom, accounting for around a fifth of all cancer deaths. Lung, bowel, prostate and breast cancers account for 45% of the United Kingdom’s cancer deaths, the NHS said.

U.S. life sciences company Illumina Inc said last month it had completed its $7.1 billion acquisition of Grail. Illumina said it will operate Grail separately from its existing business.

Related posts

J&J says second shot boosts protection to 94%

Reuters News Service

Calls grow among experts in Singapore for a vaccine mandate as Covid -19 spikes

Reuters News Service

Pfizer/BioNTech say data show Covid-19 vaccine safe and protective in kids

Reuters News Service

Flu jabs available from beginning of October

Staff Reporter

Gesy budget well within estimates, HIO says

Gina Agapiou

US booster debate moves to FDA vaccine advisory committee

Reuters News Service